Cardiff Oncology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cardiff Oncology Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CRDF
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001213037
Board of directors
-
Gary W. Pace · DirectorSince 2023
-
James O. Armitage · DirectorSince 2023
-
Lale White · DirectorSince 2023
-
Mani Mohindru · Director · Chief Executive OfficerSince 2023
-
Mark Erlander · Director · Chief Executive OfficerSince 2023
-
Renee P. Tannenbaum · DirectorSince 2023
-
Rodney S. Markin · DirectorSince 2023
Chief executives
Mark Erlander
· Chief Executive Officer
Dates unknown
Dates unknown
Board connections
3 of this board's directors also sit on 3 other boards.
- via Renee P. Tannenbaum
- via Mani Mohindru
- via Gary W. Pace
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,116,490
- 4 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 14, 2026 | Mani Mohindru Director, Officer (Chief Executive Officer) | Open-market purchase | +34,364 | $1.46 | $50,000 |
| Jul 14, 2026 | Gary W. Pace Director | Open-market purchase | +687,285 | $1.46 | $1,000,000 |
| Jun 18, 2026 | Mani Mohindru Director, Officer (Chief Executive Officer) | Open-market purchase | +24,703 | $1.21 | $29,891 |
| Jun 18, 2026 | Gary W. Pace Director | Open-market purchase | +30,000 | $1.22 | $36,600 |
| Jul 30, 2025 | Gary W. Pace Director | Open-market purchase | +275,000 | $2.45 | $673,750 |
| Jul 30, 2025 | Gary W. Pace Director | Open-market purchase | +15,000 | $2.45 | $36,750 |
| Dec 18, 2024 | Levine James E. Officer (Chief Financial Officer) | Open-market purchase | +2,400 | $5.00 | $12,000 |
| Dec 17, 2024 | Levine James E. Officer (Chief Financial Officer) | Open-market purchase | +2,752 | $5.42 | $14,916 |
| Dec 16, 2024 | Levine James E. Officer (Chief Financial Officer) | Open-market purchase | +2,564 | $3.83 | $9,820 |
| Dec 12, 2024 | Renee P. Tannenbaum Director | Open-market purchase | +10,000 | $3.42 | $34,200 |
| Dec 11, 2024 | Gary W. Pace Director | Open-market purchase | +350,115 | $2.60 | $910,299 |
| Dec 11, 2024 | Gary W. Pace Director | Open-market purchase | +11,500 | $2.60 | $29,900 |
| Dec 19, 2023 | Gary W. Pace Director | Open-market purchase | +30,000 | $1.37 | $41,100 |
| Nov 10, 2023 | Gary W. Pace Director | Open-market purchase | +22,950 | $0.98 | $22,491 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.